Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $9.52 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.